Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24873117 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL4769824 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL21646851 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL3508948 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL7432218 | 0.77 | ALDH1A1 (0.46) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL8914641 | 0.76 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL21065585 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL17162119 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAHTTALDH1A1L3MBTL1 | |
| SCHEMBL852589 | 0.75 | LTA4H (0.64) | SMN1; SMN2LMNAHTTALDH1A1MAPT | |
| SCHEMBL7749694 | 0.74 | SMN1; SMN2 (0.82) | SMN1; SMN2LMNAHTTL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | SONATA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | GRK2, GRK3, GRK1 | SMN1; SMN2 2194/4885LMNA 3887/4885HTT 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.